Skip to main content
Clinical Trials/NCT03305692
NCT03305692
Completed
N/A

Optimization of New CRT Recipients: Subjects Randomized to ECG Belt or Echocardiographic Optimization

Alan J. Bank, MD1 site in 1 country3 target enrollmentOctober 31, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure, Systolic
Sponsor
Alan J. Bank, MD
Enrollment
3
Locations
1
Primary Endpoint
Echocardiographic assessment of LV size
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Cardiac resynchronization therapy (CRT) has been a valuable intervention for patients with systolic heart failure for over 15 years. Despite years of research, there is a still a 25-40% non-responder rate depending on the outcomes measured. CRT optimization is a term used to describe the act of individualizing the therapy (CRT programming) for an individual patient. This is not often performed, but when it is, echocardiography is utilized. Recent work of body surface mapping using a novel system called the ECG Belt has shown a relationship between measures of electrical dyssynchrony and acute and chronic heart pumping function. This study will compare outcomes of patients randomized to either echocardiographic or ECG Belt optimization of CRT devices.

Detailed Description

This is a prospective randomized study designed to determine whether cardiac resynchronization therapy (CRT) device programming guided by the ECG Belt (Medtronic, PLC) improves echocardiographic and functional outcomes in heart failure (HF) patients. The population will include patients treated with CRT for standard indications (not implanted for the sole purposes of this study). The study will focus enrollment on patients who do not have baseline characteristics predicting the best CRT response. Therefore the study will not enroll patients having non-ischemic HF etiology, left bundle branch (LBBB) morphology, and QRSd \> 150 ms or those previously RV paced.

Registry
clinicaltrials.gov
Start Date
October 31, 2017
End Date
August 17, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Alan J. Bank, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Alan J. Bank, MD

Medical Director of Research - United Heart & Vascular Clinic

Allina Health System

Eligibility Criteria

Inclusion Criteria

  • Willing and able to provide informed consent for participation in the study
  • Age ≥18 years
  • Received a first-time CRT device for standard clinical indication (can be upgraded from non-CRT pacemaker or defibrillator if ventricular pacing \< 10%)
  • Adequate echocardiographic images for EF \& LVESV determination

Exclusion Criteria

  • Unhealed open wounds on the torso and/or a history of documented severe allergic reactions from ECG electrode gel
  • Enrollment in a concurrent study that could confound the results of this study
  • Pregnant or could become pregnant within the 6 month follow-up period
  • Non-ischemic cardiomyopathy, LBBB morphology, and QRSd \> 150 ms
  • Dysrhythmia (AF or PVCs) that will likely result in aggregate ventricular pacing \< 90% over the 6 month follow-up period

Outcomes

Primary Outcomes

Echocardiographic assessment of LV size

Time Frame: 6 months post optimization

Change in left ventricular end-systolic volume

Echocardiographic assessment of LV function

Time Frame: 6 months post optimization

Change in ejection fraction

Study Sites (1)

Loading locations...

Similar Trials